The pharmacokinetic profile of triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) and its main metabolite HTB (2-hydroxy-4-trifluoromethyl benzoic acid) has been studied in 8 healthy subjects (4 males and 4 females), after a single oral dose of 900 mg of triflusal. Plasma concentrations were determined by a sensitive HPLC method. Sampling was performed up to 120 h post medication. Triflusal displays a Cmax of 11.6±1.7 μg/ml and a tmax of 0.88±0.26 h. The elimination half-life (t1/2) was 0.55 h with a clearance (Cl/F) of 45.5±11.0 1/h. HTB kinetic parameters were: tmax 4.96±1.37 h and Cmax 92.7±17.1 μg/ml, with an elimination t1/2 of 34.3±5.3 and a clearance of 0.18±0.041/h. The results obtained in this study show a rapid absorption of triflusal and an immediate biotransformation into HTB. The long lasting platelet anti-aggregatory effect of triflusal in spite of its short t1/2 could be explained by the irreversible inhibition of platelet cyclo-oxygenase and the sustained levels of HTB, which also possess anti-aggregant properties. © 1991 Springer-Verlag.
|Journal||European Journal of Drug Metabolism and Pharmacokinetics|
|Publication status||Published - 1 Oct 1991|
- platelet anti-aggregants